发明名称 |
Treatment of circadian rhythm disorders |
摘要 |
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. |
申请公布号 |
US9539234(B2) |
申请公布日期 |
2017.01.10 |
申请号 |
US201514688301 |
申请日期 |
2015.04.16 |
申请人 |
Vanda Pharmaceuticals, Inc. |
发明人 |
Dressman Marlene Michelle;Feeney John Joseph;Licamele Louis William;Polymeropoulos Mihael H. |
分类号 |
A61K31/343;A61K31/00;G01N33/68;A61K9/00 |
主分类号 |
A61K31/343 |
代理机构 |
Hoffman Warnick LLC |
代理人 |
Hoffman Warnick LLC |
主权项 |
1. A method of treating a patient for a circadian rhythm disorder wherein the patient is being treated with a strong CYP1A2 inhibitor selected from a group consisting of fluvoxamine, ciprofloxacin, and verapamil, the method comprising:
discontinuing the treatment with the strong CYP1A2 inhibitor; and then treating the patient with tasimelteion, thereby avoiding the use of tasimelteon in combination with the strong CYP1A2 inhibitor. |
地址 |
Washington DC US |